EMA Authorised: Enzalutamide Viatris (enzalutamide) — Viatris Limited

View source ↗

Summary

EMA authorised a generic version of enzalutamide (Enzalutamide Viatris) for prostatic neoplasms, with Viatris Limited as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostatic Neoplasms

Drugs mentioned

• Enzalutamide Viatris (enzalutamide)

Snippet

Status: Authorised. Therapeutic area: Prostatic Neoplasms. MAH: Viatris Limited. Decision date: 23/02/2026